Cytek Biosciences Stock Buy Hold or Sell Recommendation
| CTKB Stock | USD 4.08 0.14 3.32% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Cytek Biosciences is 'Sell'. Macroaxis provides Cytek Biosciences buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CTKB positions.
Check out Cytek Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide. In addition, we conduct extensive research on individual companies such as Cytek and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
Cytek |
Execute Cytek Biosciences Buy or Sell Advice
The Cytek recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cytek Biosciences. Macroaxis does not own or have any residual interests in Cytek Biosciences or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cytek Biosciences' advice using the current market data and latest reported fundamentals.
Time Horizon
3 Months |
Risk Tolerance
I am an educated risk taker |
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Cytek Biosciences Trading Alerts and Improvement Suggestions
| Cytek Biosciences generated a negative expected return over the last 90 days | |
| Cytek Biosciences has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 200.45 M. Net Loss for the year was (6.02 M) with profit before overhead, payroll, taxes, and interest of 111.11 M. | |
| Cytek Biosciences has a poor financial position based on the latest SEC disclosures | |
| About 61.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Cytek Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek Muse Micro System |
Cytek Biosciences Returns Distribution Density
The distribution of Cytek Biosciences' historical returns is an attempt to chart the uncertainty of Cytek Biosciences' future price movements. The chart of the probability distribution of Cytek Biosciences daily returns describes the distribution of returns around its average expected value. We use Cytek Biosciences price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cytek Biosciences returns is essential to provide solid investment advice for Cytek Biosciences.
| Mean Return | -0.59 |
| Value At Risk | -5.17 |
| Potential Upside | 4.66 |
| Standard Deviation | 3.95 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cytek Biosciences historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Cytek Stock Institutional Investors
| Shares | |||
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.1 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 1.1 M | |
| Jpmorgan Chase & Co | 2024-12-31 | 947.7 K | |
| Millennium Management Llc | 2024-12-31 | 803.9 K | |
| Bank Of New York Mellon Corp | 2024-12-31 | 730.7 K | |
| Fmr Inc | 2024-12-31 | 683.2 K | |
| Ubs Group Ag | 2024-12-31 | 665.7 K | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 601.7 K | |
| Principal Financial Group Inc | 2024-12-31 | 506.9 K | |
| Blackrock Inc | 2024-12-31 | 18.5 M | |
| Vanguard Group Inc | 2024-12-31 | 11.7 M |
Cytek Biosciences Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (5.7M) | (7.1M) | (17.7M) | 4.3M | 14.8M | 15.5M | |
| Investments | (1.5M) | (21.0M) | (1.6M) | (174.0M) | (83.0M) | (78.8M) | |
| Change In Cash | 135.6M | 198.5M | (65.1M) | (131.9M) | (68.9M) | (65.4M) | |
| Free Cash Flow | 13.6M | 266K | (22.1M) | 454K | 21.9M | 22.9M | |
| Depreciation | 603K | 1.2M | 5.7M | 9.2M | 10.5M | 11.0M | |
| Other Non Cash Items | 323K | 2.0M | 3.0M | (3.3M) | (3.1M) | (2.9M) | |
| Capital Expenditures | 1.5M | 4.4M | 9.9M | 4.8M | 3.5M | 4.6M | |
| Net Income | 19.4M | 3.0M | 2.5M | (12.1M) | (6.0M) | (5.7M) | |
| End Period Cash Flow | 166.1M | 364.6M | 299.5M | 167.6M | 98.7M | 93.8M |
Cytek Biosciences Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cytek Biosciences or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cytek Biosciences' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cytek stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.6 | |
β | Beta against Dow Jones | 0.54 | |
σ | Overall volatility | 4.08 | |
Ir | Information ratio | -0.15 |
Cytek Biosciences Volatility Alert
Cytek Biosciences exhibits very low volatility with skewness of -2.34 and kurtosis of 11.99. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cytek Biosciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cytek Biosciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Cytek Biosciences Fundamentals Vs Peers
Comparing Cytek Biosciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cytek Biosciences' direct or indirect competition across all of the common fundamentals between Cytek Biosciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cytek Biosciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cytek Biosciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cytek Biosciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cytek Biosciences to competition |
| Fundamentals | Cytek Biosciences | Peer Average |
| Return On Equity | -0.0153 | -0.31 |
| Return On Asset | -0.0291 | -0.14 |
| Profit Margin | (0.03) % | (1.27) % |
| Operating Margin | 0.01 % | (5.51) % |
| Current Valuation | 264.35 M | 16.62 B |
| Shares Outstanding | 128.1 M | 571.82 M |
| Shares Owned By Insiders | 8.90 % | 10.09 % |
| Shares Owned By Institutions | 61.33 % | 39.21 % |
| Number Of Shares Shorted | 3.46 M | 4.71 M |
| Price To Book | 1.33 X | 9.51 X |
| Price To Sales | 2.70 X | 11.42 X |
| Revenue | 200.45 M | 9.43 B |
| Gross Profit | 111.11 M | 27.38 B |
| EBITDA | (20.52 M) | 3.9 B |
| Net Income | (6.02 M) | 570.98 M |
| Cash And Equivalents | 349.89 M | 2.7 B |
| Cash Per Share | 2.60 X | 5.01 X |
| Total Debt | 7.55 M | 5.32 B |
| Debt To Equity | 0.04 % | 48.70 % |
| Current Ratio | 10.47 X | 2.16 X |
| Book Value Per Share | 3.06 X | 1.93 K |
| Cash Flow From Operations | 25.38 M | 971.22 M |
| Short Ratio | 4.43 X | 4.00 X |
| Earnings Per Share | (0.05) X | 3.12 X |
| Target Price | 6.9 | |
| Number Of Employees | 648 | 18.84 K |
| Beta | 1.42 | -0.15 |
| Market Capitalization | 540.57 M | 19.03 B |
| Total Asset | 499.5 M | 29.47 B |
| Retained Earnings | (35.2 M) | 9.33 B |
| Working Capital | 328.78 M | 1.48 B |
| Net Asset | 499.5 M |
Note: Acquisition by Barnett Valerie of 10313 shares of Cytek Biosciences subject to Rule 16b-3 [view details]
Cytek Biosciences Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cytek . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Cytek Biosciences Buy or Sell Advice
When is the right time to buy or sell Cytek Biosciences? Buying financial instruments such as Cytek Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Cytek Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sovereign ETFs Thematic Idea Now
Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sovereign ETFs theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sovereign ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Cytek Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.735 | Earnings Share (0.05) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets |
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.